See every side of every news story
Get Started
SubscribeLogin
Donald Trump
Everton
Ukraine War
Volodymyr Zelenskyy
Hamas
Viktor Orbán
Israel-Hamas Conflict
Basketball
Soccer
Elon Musk
Manchester United
Premier League
Published • loading... • Updated

#Neumora Therapeutics KOASTAL-1 Study of Navacaprant Under Increased Competitive Pressure

Summary by csimarket.com
'Abstract:' Neumora Therapeutics Inc. has recently released the findings from its KOASTAL-1 study, which evaluated the efficacy of Navacaprant as a treatment for Major Depressive Disorder (MDD). The study, however, did not meet its primary endpoint of demonstrating statistically significant improvement in depressive symptoms as measured by the Montgomery-'sberg Depression Rating Scale (MADRS) total score over placebo. This report outlines the st…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
Endpoints NewsEndpoints News

Neumora fails Ph3 depression study; Our review of 2024 megarounds; Pfizer cuts Sangamo pact; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints ...

Read Full Article
csimarket.comcsimarket.com

#Neumora Therapeutics KOASTAL-1 Study of Navacaprant Under Increased Competitive Pressure

'Abstract:' Neumora Therapeutics Inc. has recently released the findings from its KOASTAL-1 study, which evaluated the efficacy of Navacaprant as a treatment for Major Depressive Disorder (MDD). The study, however, did not meet its primary endpoint of demonstrating statistically significant improvement in depressive symptoms as measured by the Montgomery-'sberg Depression Rating Scale (MADRS) total score over placebo. This report outlines the st…

Read Full Article
DataemiaDataemia

Readout Newsletter: Neumora, Merck, Roche news

Sign up for the biotech newsletter to stay updated on the latest science and politics in the industry. Merck has cut the price of its diabetes drug Januvia, citing reasons related to patient benefits and changes in the Medicaid rebate program. Neumora’s experimental depression drug failed in a Phase 3 study, causing a significant drop in the company’s stock. There is a suggestion to split the FDA into two entities for better regulation and publi…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Dataemia broke the news in on Friday, January 3, 2025.
Sources are mostly out of (0)

Similar News Topics

Science

Science

Merck

Merck

News
For You
Search
BlindspotLocal